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Risk stratification has become increasingly important in the management of patients with suspected or known ischaemic heart disease (IHD).
Recent guidelines recommend that these patients have their care driven by risk assessment. The purpose of this position statement is to sum-
marize current evidence on the value of cardiac single-photon emission computed tomography, positron emission tomography, and hybrid
imaging in risk stratifying asymptomatic or symptomatic patients with suspected IHD, patients with stable disease, patients after coronary revas-
cularization, heart failure patients, and specific patient population. In addition, this position statement evaluates the impact of imaging results on
clinical decision-making and thereby its role in patient management. The document represents the opinion of the European Association of
NuclearMedicine (EANM)CardiovascularCommittee andof the EuropeanAssociationofCardiovascular Imaging (EACVI) and intends to stimu-
late future research in this field.
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Introduction
Risk stratification has become increasingly important in the manage-
ment of patients with ischaemic heart disease (IHD). Recent guide-
lines recommend that patients with suspected or known IHD have
their care driven by risk assessment.1 The association between risk
assessment and medical intervention is based on the concept that
optimal improvement in outcome is achieved by linking high-risk
measures, obtained by the different imaging modalities, to risk-
reducing therapies. In this era, new and existing technologies
require a well-defined body of evidence on its benefit, to support
resource utilization. Myocardial perfusion imaging (MPI) is the most
widely used stress imaging procedure in the management of patients
with IHD.2 Gated single-photon emission computed tomography
(SPECT) and positron emission tomography (PET) MPI provide
important prognostic information on the extent and severity of
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myocardial perfusion abnormalities, including myocardial ischaemia.
The results, obtainedbySPECTandPET, specify the functional signifi-
cance of the disease state and its relationship to event risk. On the
other hand, hybrid cardiac imaging, either with SPECT or PET com-
bined with coronary computed tomography angiography (CCTA),
depicts cardiac and vascular anatomical abnormalities and their func-
tional consequences in a single setting. This combination of techni-
ques appears to offer superior information compared with either
stand-alone or side-by-side interpretation of the data sets in patients
with suspected or known IHD.3 The purpose of this position state-
ment is to summarize current evidence on the value of cardiac
SPECT, PET, and hybrid imaging in risk stratifying specific categories
of patientswith suspected or known IHD. In addition, it evaluates the
impact of imaging results on clinical decision-making and thereby its
role in patient management. The document represents the opinion
of the European Association of Nuclear Medicine (EANM) Cardio-
vascular Committee and of the European Association of Cardiovas-
cular Imaging (EACVI) and intends to stimulate future research in
this field.
Patients with suspected IHD
Asymptomatic patients
Approximately half of acute coronary syndromes occur in patients
who were asymptomatic until the day of their event, of which 48%
have only one or even none of the traditional risk factors.4 This has
prompted a demand for effective screening tools to reduce the
high toll of unexpected coronary events by more individualized risk
stratification. The use of imaging, in particular MPI, for the screening
of asymptomatic but potentially hazardous IHD is a highly debated
topic of preventive cardiology. Several expert consensus documents
and international guidelines have given controversial recommenda-
tions.5 Those who are in favour of imaging-based screening
agree upon its potential value in selected high-risk populations.6
However, until now conclusive evidence is lacking that detecting
asymptomatic preclinical IHD by MPI with subsequent therapeutic
intervention may reduce risk, beyond that indicated by risk factor
profiling and traditional conservative risk reduction strategies.
Thus, clinical risk assessment forms the basis for deciding on the in-
tensity of additional screening with MPI, especially in selected high-
risk population. Coronary artery calcium score (CACS) was pro-
posed as a gatekeeper to identify asymptomatic subjects at risk for
which further screening radionuclide MPI may be justified.7 Indeed,
abnormal myocardial perfusion is rare below a CACS threshold of
100, but the prevalence of abnormal scans increases progressively
with higher CACS. Notably, moderate-to-severe myocardial ischae-
mia was found in 8.6% of patients with CACS ≥1000. Several pro-
spective follow-up studies indicate that the use of CACS and
radionuclide MPI has additional prognostic value (albeit mainly in
symptomatic patients). In particular, an incremental prognostic
value of CACS in 977 asymptomatic patients with normal MPI was
reported.8 There was a 3.6-fold relative increase for any cardiac
event and a 2.8-fold relative increase for death/myocardial infarction
when the CACS was severe (.400) vs. minimal (≤10). Based on
these data, the Appropriate Use Criteria consider screening with
MPI appropriate in asymptomatic patients with a CACS .400, or a
CACSbetween100 and 400 and high IHDrisk by traditional criteria.6
Silent myocardial ischaemia is also highly prevalent (27%) in asymp-
tomatic male siblings of patients with onset of IHD before the age
of 60 years and is independently associated with incident IHD (in
two-thirds with an acute coronary syndrome) during the ensuing
10 years.9 Therefore, some investigators have suggested a tiered
screening approach to subjects with a family history of premature
IHD where a CACS could be used as gatekeeper of screening
MPI.10 Non-invasive quantification of absolute myocardial blood
flow by PET allows the detection of abnormal vasodilatory response
to intravenous adenosine patients with a family history of CAD and
high-risk lipid profiles. Early assessment of alterations of vascular re-
activity to adenosine in relation to high-risk lipid profiles in asymp-
tomatic patients may allow early detection of preclinical
atherosclerosis and may initiate modification and/or elimination of
risk factors.11
Symptomatic patients
The prognostic value of MPI with SPECT in symptomatic patients
with suspected IHD has been validated extensively. Pooled analyses
from large observational databases comprising close to 40 000
patients unambiguously demonstrate that a normal MPI yields a fa-
vourable prognosis with an annualized event rate of 0.6%, which is
similar to the general population.12 Although the warranty period
of a normal MPI interacts with the patient’s risk profile, a low event
rate has been reported for over a period as long as 7 years.13 Con-
versely, an abnormal scan confers a three- to seven-fold increase in
annual cardiac events. The likelihood of events is related to the
extent and severity of perfusion defects, fixed and/or reversible,
and the associated prognostic risk needs to be interpreted in light
of the baseline risk profile of the individual patient.14 Next to perfu-
sion assessment, important additional prognostic information can be
retrieved from the acquired SPECT, that is, left ventricular (LV)
volumes and function (e.g. ejection fraction). A clear relationship
between the extent of LV dysfunction and prognosis, independent
from clinical baseline characteristics or perfusions defects, has been
demonstrated. As well, evaluation of transient LV dilatation has
been linked to extensive IHDdue topost-stress LVdysfunction.15Al-
though risk stratification with SPECT imaging is important, improve-
ment of prognosis through an imaging-guided approach is an obvious
superior goal. Hachamovitch et al.16 have suggested that revascular-
ization proceduresmight be beneficial to impact outcome only in the
presence of ischaemia involving 10% ormore of the LVmyocardium.
In a prospective nuclear sub-studyof theCOURAGE trial, this notion
was underscored, whereby an ameliorated prognosis seemed to be
related to the extent of ischaemia reduction as displayed with
SPECT.17 These overwhelming data highlight that SPECT has power-
ful prognostic value but may additionally be used to guide patient
management to influence outcome. In analogy to SPECT, PET
holds strong prognostic information beyond traditional cardiovascu-
lar risk factors.18 In contrast to SPECT, PET offers the possibility to
routinely quantify perfusion in absolute terms and calculate coronary
flow reserve (CFR), which has incremental prognostic value over
evaluation of perfusion defects alone. Murthy et al.18 demonstrated
that a blunted CFR was one of the strongest prognostic factors and
trumps clinical risk scores as well as relative perfusion abnormalities.
Interestingly, apparent normal perfusion images with a homogenous
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tracer distribution can be reclassified based on diffusely blunted
hyperaemic myocardial blood flow (MBF) or CFR. Several studies
have revealed that this subset of patients is at increased risk for
future cardiac events.19
Combining CACS with MPI adds incremental prognostic value in
patients with and without myocardial ischaemia, although ischaemia
appears to be a more potent predictor of future cardiac events than
coronary calcification.8 Improved risk stratification, by adding ana-
tomical information of CCTA to functional data obtained with MPI,
has also been documented. Pioneering studies documented the po-
tential roleof PET/CT technique to add functional informationon the
pathophysiological impact of a lesion, allowing accurate clinical
decision-making on the best therapeutic strategy.20 Interestingly,
hybrid PET/CT allowed combination of angiography and perfusion
imaging in short, quantitative, low-radiation-dose protocols.21 The
likelihoodof diagnosingobstructive IHDby invasivecoronaryangiog-
raphy (ICA) is highest when patients have been screened with a
hybrid imaging protocol, and both CCTA and MPI revealed abnor-
malities.22 Also the use of a sequential imaging approach provides
particular additional value to risk stratify patients when either func-
tional or anatomical evaluation displays ambiguous results.23 On
the other hand, annualized even rate of a normal MPI significantly
increases when CCTA displays a coronary lesion of .50% (0.6 vs.
3.8%). The general consensus of the aforementioned studies is that
hybrid assessment provides complementary rather than overlapping
prognostic information. Such an approachcan accurately position the
patient within the various stages of atherosclerosis.3
Patients with known IHD
In patients with known IHD, atherosclerotic changes in the coronary
arteries have to be taken for granted. Therefore, testing for ischaemia
mayadd themost important information for further decision-making,
especially, since secondary prevention should have already been
initiated at the point of IHD diagnosis. Taking into account that
IHD is a chronic progressive disease, re-evaluation of IHD risk may
be beneficial. Serial testing using MPI is widely used in guiding
patient caredespite the lackofwell-defined appropriate use criteria.2
Thefirst prospective assessmentof appropriate useofMPS regarding
its prognostic value in a patient population with known or suspected
IHD demonstrated higher inappropriate use rates compared with
previous reports, also demonstrating that the inappropriate use of
MPI impaired its value for risk stratification.24 Although this study
has some important caveats, it demonstrated the necessity for
more data, studying the variability in inappropriate rates and the
prognostic value of appropriate use criteria in other specific patient
populations.
Stable IHD
In the follow-up of patients with stable IHD, no randomized trials are
available evaluating the impact on outcome of different strategies.
Despite no data suggest that any form of routine stress testing or
imaging improve outcome, repeat risk stratification may be consid-
ered after expiration of the ‘warranty period’ of an examination. Mul-
tiple clinical factors play an important role in patients with normal
MPI, affecting their risk and altering the duration of a ‘warranty
period’ for a normal perfusion scan.25 A patient-tailored approach
based on clinical judgement has to be used to determine the benefits
and risks of repeat risk stratification by cardiac imaging. Serial MPI
provides valuable means to guide patient management and to study
the impact of various interventions.2 In particular, serial imaging
may be useful in both clinical and research arenas to assess the
value of novel anti-ischaemic therapies. The concerns of radiation ex-
posurehavebeenaddressedbyMPI technology innovation.Thenew-
generation cadmium-zinc-telluride (CZT) gamma cameras, which
allow acquisition of high-quality images using smaller doses of radio-
tracer (Figure 1), have the potential for decrease patient radiation ex-
posure also for hybrid imaging (Figure 2). That represents one of the
main reached goals in using radionuclide MPI in guiding patient man-
agement. In patients with multi-vessel disease or complex IHD, the
difficulties in identifying balanced flow reduction can be overcome
withquantitativemyocardial perfusionmeasuresbyPET.Abetter de-
lineation of at-risk myocardium with quantitative CFR may also
improve risk stratification in patientswith known IHD. As underlined
by the INSPIRE (Adenosine Sestamibi Post-Infarction Evaluation)
study, MPI early after myocardial infarction was a safe and effective
risk stratification strategy for identifying a large low-risk population
that could be targeted for medical therapy and early hospital dis-
charge.26 Moreover, in patients with remote prior myocardial infarc-
tion, MPI added incremental value to pre-scan information and was
highly predictive and cost-efficient in the risk stratification of these
patients.27 Patients with known IHD who underwent serial MPI
imaging demonstrated that adding PCI to optimal medical therapy
resulted in greater reduction in inducible ischaemia compared with
optimal medical therapy alone. This benefit was most pronounced
among patients with more severe baseline ischaemia (Figure 3).
Finally, the magnitude of residual ischaemia on follow-up MPI was
proportional to the risk for death orMI, and a 5% reduction in ischae-
mia was associated with a significant reduction in risk.16
Patients after revascularization
In symptomatic patients after PCI and coronary artery bypass grafting
(CABG), MPI testing is appropriate28 for diagnosis, risk stratification,
and clinical decision-making. On the contrary, in asymptomatic
patients after PCI and CABG, MPI rarely is appropriate, except in
case of incomplete revascularization, or if performed .2 years
after PCI or .5 years after CABG. The appropriateness of MPI in
these patients is based on the incremental prognostic value of MPI
after revascularization.29 Evidence of silent ischaemia 6 months
after PCI predicted a worse outcome and tended to have a better
outcome than symptomatic ischaemia. Even 5 years after PCI, target-
vessel events weremore frequent than IHD progression assessed by
remote events. However, remote events, often silent, accounted
for up to 40% of all adverse events. This observation underscores
the importance of IHD progression and of optimized secondary pre-
vention strategies in addition to revascularization.29 In selected
CABG patients, hybrid imaging PET or MPI combined with CTCA
may provide important information for further risk stratification.30
Heart failure
Heart failure (HF) is acomplexclinical syndromethat results fromany
structural or functional impairment of ventricular filling or ejection of
blood: either with a reduced (,50%) or preserved EF (≥50%). In
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addition to existing medical therapies for HF that have been success-
ful in reducingmortality and extending survival, there has been a rapid
increase in the use of implantable devices. All together these evolu-
tions have an increasing impact on healthcare budgets. Therefore,
better treatments for and earlier detection of HF are imperative.
The dramatic deterioration in quality of life and prognosis when a
patient progresses from asymptomatic LV dysfunction to overt HF
suggests that only a programme of screening and prevention will ef-
fectively reduce the public health burden. Moreover, the economic
consequences of developing overt HF suggest that such an approach
is likely to be cost-effective. The 2013 American College of Cardi-
ology Foundation (ACCF)/AHA guidelines on HF recommended
that cardiac catheterizationwith coronary angiography is reasonable
in patients with new onset HF of uncertain cause who would be eli-
gible for revascularization.31Non-invasive imaging to detectmyocar-
dial ischaemia and viabilitywas considered reasonable in IHDpatients
with no angina and newonset HF, assuming that the patient is eligible
for revascularization. The guidelines also noted that non-invasive
imaging might be considered to define the likelihood of IHD in
other patients with HF and LV dysfunction. This is in line with the
2012 ESC guidelines for the diagnosis and treatment of HF, that
give a IIA recommendation for considering MPI in HF patients
thought to have IHD to determine extension of ischaemia and viabil-
ity before revascularization. As a matter of fact, the appropriate
patient selection for revascularization procedures is crucial and
should be based on an accurate assessment of both possible risks
and benefits. The assessment of myocardial viability has been an
important prerequisite in the decision-making regarding revasculari-
zation as supported by a meta-analysis showing that after revascular-
ization patients with myocardial viability had a better outcome
compared with those without myocardial viability.32 However,
after the STICH (Surgical Treatment for Ischemic Heart Failure)
trial and especially the viability sub-study, questions have arisen
regarding assessing viability testing in patients with LV systolic dys-
function and IHD before revascularization.33 The STICH study
reported no impact of viability on the primary end point of all-cause
mortality in patients with ischaemic severe HF randomized to revas-
cularization or optimal medical therapy. The STICH trial presented
some limitations; the main methodological one was the definition
of myocardial viability. A significant reduction in cardiac events in
patients with LV dysfunction and suspected coronary disease for
FDG PET-assisted management vs. standard care has been
Figure 1 Case example. Dipyridamole-rest low-dose cadmium-zinc-telluride MPI (dosimetry 4.3 mSv). Asymptomatic male (55 years) with dia-
betes, normal resting function and negative stress test. MPI images showed perfusion defects (white arrows) of the distal anterior, anterior septum,
and apical walls (LAD territory). An intermediate stenosis of the marginal branch of the left circumflex coronary artery (white arrows) does not
correspond to any reduction of flow reserve. The main lesion was successfully treated by angioplasty.
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demonstrated.34 Current HF guidelines recommended consider-
ation of non-invasive imaging for the assessment of both inducible is-
chaemia and viable myocardium in the HF population. Early
revascularization in the setting of significant hibernatingmyocardium
was associated with improved survival compared with medical
therapy, especially when the extent of viability exceeded 10% of
the myocardium.35
Myocardial 123I-meta-iodobenzylguanidine (123I-mIBG) scintig-
raphy reflects the cardiac sympathetic activity. Recently, 123I-mIBG
scintigraphy has been shown to be an independent predictor of ven-
tricular arrhythmia, sudden cardiac death, and appropriate ICD dis-
charges in HF patients with NYHA II-III and LV ejection fraction
≤35%.36 However, 123I-mIBG scintigraphy is not included in the
current HF guidelines. This may be explained, in part, by the relative
lack of large patient cohort trials. In addition, the role of cardiac in-
nervation imaging techniques in identifying high-risk patients with
mild tomoderate systolic dysfunction (EF.35%) has not been inves-
tigated yet.
Specific patient population
Women
Despite the recent decline in cardiovascular death rate in women,
IHD is still the prevalent cause of mortality in women. Given the
lower prevalence of obstructive IHD, greater variety of (atypical)
symptoms, and commonly lower functional capacity, detection of
IHD can be challenging in women despite there are no differences
between women and men in the diagnostic evaluation. Recent data
of ‘What Is the Optimal Method for Ischemia Evaluation in Women
(WOMEN)’ trial endorse the use of exercise tolerance test (ETT)
with the possibility for follow-up evaluation with stress MPI for
Figure 2 Case example. Hybrid images (MPI by CZT and CCTA, dosimetry 5.7 mSv). Female (65 years), several risk factors, previous percutan-
eous coronary revascularization procedureon left circumflexcoronaryartery andnewonset of atypical angina.CCTAshowed significant stenosis of
right coronary artery, with reduction of flow after stress in the same territory documented by stressMPI (white arrows). The fusion images showed
concordance between coronary anatomy and functional evaluation.
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women with indeterminate or abnormal electrocardiographic and/
or other ETT alterations. Such a strategy yielded comparable
2-year rates of major adverse IHD outcome.37 In women with
normal MPI, even in those women with high pre-test likelihood, the
cardiac event rate is,1%.36Comparedwith a general cardiovascular
risk population, the size and severity of the perfusion abnormality are
also paralleled with an increase in cardiac event rate.38 Perfusion
imaging by PET or PET/CT has the same advantages as for male sub-
jects over SPECTowing to improved spatial resolution, imagequality,
reduction in breast artefacts, lowered radiation exposure, and possi-
bility to quantifyMBF andCFR.Applying resting/stress 82Rb-PETper-
fusion imaging, 5-year IHD mortality ranged from 0.9 to 13% for
women with 0 to ≥15% stress-induced myocardial perfusion
defects.39 Reductions in hyperaemic MBFs and CFR have been
reported to carry important diagnostic and prognostic information
in cardiovascular risk individuals with or without clinically manifest
IHD. It has been demonstrated that coronarymicrovascular dysfunc-
tion identifiesmenandwomenat increasedclinical risk.40 In this scen-
ario, PETflowstudies havedemonstrated thathormone replacement
therapy with oestrogen alone or in concert with progesterone in
post-menopausal women, in addition to standard preventive
medical intervention of traditional cardiovascular risk factors, may
contribute topreservemyocardial perfusionand the functional integ-
rity of coronary circulatory function.41
Diabetic patients
Type 1 and type 2 diabetes mellitus (DM) is commonly paralleled by
the early development of accelerated IHD that is held responsible for
excess morbidity and mortality in these patients. Diabetic patients
have a high risk for cardiovascular events and tend to have more
often silent CAD than non-diabetic patients.42 It has been demon-
strated that presence of perfusion abnormalities in diabetic patients
confer a significantly worse prognosis, in particular in women and
insulin-dependent individuals, than comparable perfusion abnormal-
ities in patients without diabetes.43 A normal MPI in diabetic patients
is associated with a significantly better outcome than in those with
perfusion abnormalities (annual cardiac death rate in non-insulin-
dependent DM: 1.8 vs. 4.7%; and insulin-dependent DM: 2.5 vs.
9.0%). However, the prognosis of diabetic patients was still worse
compared with non-diabetic patients. In the DIAD (Detection of Is-
chemia in Asymptomatic Diabetes) screening group, MPI was able to
accurately risk stratify patients based on perfusion findings, with a
higher event rates in patients with moderate or large perfusion
defects compared with those with only mildly abnormal or normal
MPI.44 In this study, a low prevalence of patients with high-risk MPI
abnormalities was observed, explaining probably why also screening
did not show any difference on outcome compared with aggressive
medical treatment. As a matter of fact, the 2009 ACCF/ASNC/
ACR/AHA/ASE/SCCT/SCMR/SNM Appropriate Use Criteria for
Figure3 Case example.Coronary revascularization guidedby severemyocardial ischaemia at rest-stress 82Rb-PET.Baseline stress (A) and rest (B)
myocardial perfusion imaging shows a severe myocardial ischaemia (.10%) completely resolved at stress (C) and rest (D) imaging after coronary
revascularization procedure. In the pre-procedural coronary angiography (E), thewhite arrows showoccluded II obtuse marginal branch of a dom-
inant circumflex artery of the LCA. In post-percutaneous coronary intervention angiography (F), the white arrows indicate the treated II obtuse
marginal branch with a good calibre and large extension towards the inferior and lateral wall of the left ventricle.
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CardiacRadionuclide Imaging, consider screeningwithMPI appropri-
ate in asymptomatic patients with high IHD risk or IHD risk equiva-
lents such as diabetes.6 In asymptomatic diabetic patients, analytical
approaches for stress MPS that establish the reclassification of
events may serve for estimation of improved outcomes.45 In particu-
lar, stress-induced ischaemia by gated MPI influences the temporal
characteristic of the patient’s risk at long-term follow-up. Thus, an
MPS-adjusted strategy seems to be useful to refine risk estimate in
asymptomatic diabetic subjects.45 Recently, in high-risk asymptomat-
ic patients with diabetes BARDOT (BAsel high Risk Diabetic
Outcome Trial) documented that patients with normal MPI (78%)
have a low rate of firstmanifestations of IHD. Patients with abnormal
MPI at baseline (22%) have a seven-fold higher rate of progression to
‘overt or silent IHD,’ despite therapy.46 The American Diabetes
Association’s (ADA’s) Standards of Care recommendation suggests
that routine screening for IHD in asymptomatic diabetic patients is
not recommended because it does not improve outcomes as long
as IHD risk factors are treated.47 As a matter of fact, the joint Ameri-
can Diabetes Association (ADA), European Society of Cardiology
(ESC), and European Association for the Study of Diabetes (EASD)
guidelines48 recommend IHD screening in DM with MPI when
there is evidence for atherosclerotic process or cardiac symptoms
such as (i) abnormal resting ECG, (ii) evidence of peripheral or
carotid occlusive arterial disease, and (iii) in DM patients with symp-
toms suspicious of IHD (i.e. chest pain, dyspnoea, fatigue). The role of
cardiac PET for the assessment ofmyocardial perfusion and flowmay
be seen not only in the detection of more advanced stages of IHD in
DM. In particular, PETmight be pivotal in the identification and char-
acterization of functional abnormalities of the coronary circulation,
which have been regarded as functional precursors of the IHD
process.19 Notably, among DM patients without IHD, those with
impaired CFR have event rates similar to those of patients with
known IHD. In contrast, DM patients with maintained CFR have
event rates comparably low with those without known IHD or DM
and a normal stress perfusion and systolic function.49 More recently,
glucose-lowering treatment has demonstrated that coronary
endothelial function is independently associated with a slowed
progression of coronary artery calcification in DM.50 Whether
PET-outcome-guided treatment, with the aim of improving hyper-
aemic MBF and/or CFR, will result in an improved patient outcome
in DM remains to be seen.
Elderly
Over the last decades, there has been a steady increase in the preva-
lence of individuals older than 75 years. IHD is the most prevalent
cause of morbidity and mortality in this age group, while rates have
not fallen over time as they have been observed for younger indivi-
duals.51 In a retrospective MPI study in 5200 elderly patients with a
follow-up of 2.8+ 1.7 years, cardiac death rates significantly
increased with increasing severity of abnormalities on MPI from
normal, mildly abnormal, and moderately-to-severely abnormal
myocardial perfusion with pharmacological stress (1.9 vs. 2.7 vs.
7.8%) or exercise stress (0.7 vs. 1.0 vs. 2.7%). As observed for
SPECT, PET for myocardial perfusion may aid in selecting elderly
patients at risk for cardiovascular events. However, it is important
to be aware that resting MBF is commonly higher with increasing
age related to an increase of baseline myocardial work, which again
leads to lowerCFR values.52Notably, above 70 years of age reported
that hyperaemic MBFs appear to be lower. Apart from evidence of
deficient neuroendocrine regulation of the cardiovascular system
with advancing age, a diminished effect of exogenous applied adeno-
sineonvascular smoothmuscle cell relaxationof the coronaryarteri-
olar vessels may account for the observed reduction in hyperaemic
MBF in the elderly population.52 This again emphasizes the need to
refine thresholds of hyperaemic MBFs and CFR, respectively, to dif-
ferentiate normal and abnormal values for IHD in the elderly.
Whether the assessment ofCFRwith PETmayprovide further incre-
mental value in cardiovascular risk stratification over conventional
perfusion imaging is an open question, needing further investigation.
Table 1 Key points for risk stratification in guiding
management of
Asymptomatic patients
Screening with MPI in selected high-risk populations
CACS as gatekeeper of screening MPI for patients with higher risk
coronary atherosclerosis and for low-risk patients with a family
history of premature IHD or intermediate-risk patients
Symptomatic patients
MPI has powerful prognostic value (i.e. in the presence of ischaemia
.10% ofmyocardium) andmay additionally be used to guide patient
management to influence outcome
Additional prognostic information can be retrieved by function and
volume parameters
Hybrid imaging demonstrated to improve risk stratification, by adding
anatomical information to functional data
Hyperaemic myocardial blood flow (MBF) or CFR evaluation can
reclassify patient with apparent normal perfusion images in guiding
treatment
Patients with known IHD
MPI early after myocardial infarction is a risk stratification strategy
for identifying a large low-risk population that could be targeted
for medical therapy and early hospital discharge
Quantitative CFR, with a better delineation of at-risk myocardium,
may improve risk stratification in patients with known IHD and in
patients with multi-vessel disease
In selectedCABGpatients, hybrid imaging PETorMPI combinedwith
CTCA may provide important information for further risk
stratification
Heart Failure
MPI may be reasonable to detect myocardial ischaemia and viability
in IHD patients with no angina and new onset HF eligible for
revascularization
Cardiac Innervation imagingmay be used as a predictor of ventricular
arrhythmia, sudden cardiac death
Specific population
Nodifferences betweenwomen andmen in the diagnostic evaluation
are found. Coronary microvascular dysfunction identifies both men
and women at increased clinical risk
Screening of asymptomatic diabetic patients is not recommended
In high-risk asymptomatic diabetic patients MPI screening may be
done to identify a higher risk patient subgroup
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Left bundle branch block patients
Complete left bundle branch block (LBBB) is associated with higher
adverse outcomes including major cardiac events and mortality. In
particular, LBBB occurs frequently in dilated cardiomyopathy and is
associated with high cardiac morbidity and mortality.53 LBBB
induces inhomogeneous activationanddeformationof the ventricles,
leading to inefficient contraction. Experimental data suggest that the
redistributionof localworkload inducedbyLBBBprovokes substantial
changes in regionalMBF and glucosemetabolism, alongwith structural
remodelling. Evaluation of MBF by PET should be useful to identify re-
sponse to resynchronization therapy in dilated cardiomyopathy
patients with LBBB. It has been demonstrated that LBBB induces rele-
vant abnormalities in systolic deformationof the LV regions, leading to
extensive redistribution of myocardial glucose metabolism and asym-
metric LV hypertrophy.54 Conversely, blood flows and MBF reserve
were not influenced by contraction abnormalities and thereby were
uniformly distributed across LV regions in patients with and without
LBBB, indicating that these regional changes may further promote
adverse LV remodelling leading to such extensive alterations not po-
tentially reversible by resynchronization therapy.
Conclusions
This document provides a synopsis of available evidence on the prog-
nostic value of SPECT, PET, and hybrid imaging in the evaluation of
patients with suspected or known IHD. There is a substantial body
of evidence on the prognostic role of these imaging modalities.
However, in this era of prognostication, depth of evidence needs
to be used to guide management of many important patient
subsets. Some indications highlighted herein showed a significant
role of imaging modalities in prognostication. Accordingly, k-points
of the panel are summarized in Table 1. In patients with suspected
or known IHD, current evidence shows that extent and severity of
myocardial ischaemia may be used to guide patient management to
influence outcome. However, randomized studies are currently
lacking. In addition, conclusive evidence is lacking that IHD as-
sessment of asymptomatic patients by imaging modalities with
subsequent therapeutic intervention may reduce risk beyond that
indicated by risk factor profiling and traditional conservative risk re-
duction strategies. However, in selected high-risk asymptomatic IHD
patients, additional screening with MPI can help in clinical risk assess-
ment and form the basis for clinical decision-making. It remains to be
addressed if non-invasive testing can reliably identify a considerable
proportion of patients likely to benefit from an imaging-guided inter-
vention in a cost-effective manner.
This expert panel encourages further research (Table 2) regarding
the use of imaging for risk stratification by outcome trials to evaluate
the clinical effects of imaging-based algorithms in guiding manage-
ment of patients with suspected or known IHD. Moreover, it
remains to demonstrate whether non-invasive testing can reliably
identify a considerable proportion of patients likely to benefit from
intervention in a cost-effective manner.
Conflict of interest: None declared.
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Bilateral arterial ducts with isolated left subclavian artery in
ventriculo-arterial discordance, ventricular septal defect, and coarctation
Hannah Bellsham-Revell*, Owen Miller, David Anderson, and Aaron Bell
Department of Paediatric Cardiology and Cardiothoracic Surgery, Evelina London Children’s Hospital, Westminster Bridge Road, London SE1 7EH, UK
* Corresponding author. E-mail: Hannah.bellsham-revell@gstt.nhs.uk
We report an unusual finding in a 5-day-old baby
who had had an antenatal diagnosis of ventriculo-
arterial (VA) discordance, ventricular septal
defect (VSD), and great artery disproportion, sug-
gesting postnatal development of Coarctation of
theAorta. Postnatal echocardiography confirmed
VA discordance and VSD, but the arch anatomy
was complex and less clear. There was additional
sub-aortic stenosis, which had not been fully
appreciated antenatally.
Cardiac magnetic resonance imaging (MRI)
under general anaesthesia confirmed the right aortic arch but with a severely hypoplastic transverse arch and a dominant right ductal
arch (see Supplementary data online, Video S1). A smaller left-sided arterial duct supplied the isolated left subclavian artery. The baby
remained stable on a prostaglandin infusion and underwent total correction on Day 8 of life with an arterial switch operation with VSD
closure, aortic arch reconstruction but with sacrifice of the left subclavian artery.
There have been previous descriptions of VA discordancewith a right aortic arch and coarctation, including one patientwith an isolated
left subclavian artery, but in that case it was supplied retrogradely by a vertebral artery. This appears to be the first report of this particular
constellation of bilateral ducts with an isolated left subclavian artery in VA discordance with a VSD and right-sided aortic arch with coarc-
tation.
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Panel A: Anterior view showing disconnected left subclavian supplied by left arterial duct; Panel B: Right lateral view showing severely
hypoplastic aortic arch and large right-sided ductal arch; Panel C: Left lateral view showing disconnected left subclavian and coarctation.
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